Quantcast

Latest Parkinson's disease Stories

2014-07-31 12:29:21

AFFiRiS AG presents Phase I data on a first-of-its-kind treatment with support from The Michael J. Fox Foundation NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ -- AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. The Michael J. Fox...

2014-07-31 12:29:00

DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent...

2014-07-29 08:33:46

VIENNA, July 29, 2014 /PRNewswire/ -- What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community. When: Thursday, July 31, 2014 11.00 am EST (Eastern Standard Time) 03.00 pm UTC...

2014-07-28 12:57:00

Emory University An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson’s disease, researchers at Emory University School of Medicine have shown. The results were published Thursday, July 24 in the Journal of Parkinson’s Disease. The findings demonstrate that the drug, called XPro1595, can reach the brain at sufficient levels and have beneficial effects when administered by subcutaneous injection, like an...

2014-07-28 08:30:24

ATLANTA, July 28, 2014 /PRNewswire-USNewswire/ -- RaceTrac announced that its cumulative giving to The Michael J. Fox Foundation for Parkinson's Research has exceeded $1 million. This milestone is due in large part to the continued efforts of their team members who have executed various initiatives over the years encouraging the community to participate in and support a worthy cause. "In four short years, RaceTrac has shown incredible generosity and commitment not only financially...

2014-07-24 12:28:19

More Than 30 Scientific Projects Chosen for Potential to Improve the Lives and Futures of People Touched by Parkinson's NEW YORK, July 24, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Disease Foundation® (PDF®) is pleased to announce $1.3 million in funding for more than 30 investigator-initiated research projects to help solve, treat and end Parkinson's disease. Chosen through a competitive application process, the grants reflect PDF's continued commitment to improving the...

2014-07-24 08:35:23

VIENNA, July 24, 2014 /PRNewswire/ -- What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community. When: Thursday, July 31, 2014 11.00 am EST (Eastern Standard Time) 03.00 pm UTC...

2014-07-22 16:27:02

100% of donations raised will go to research KINGSTON, N.J., July 22, 2014 /PRNewswire-USNewswire/ -- Over 11,000 people from across the country came together on Saturday, April 26(th) in New York's Central Park in support of the 2014 Parkinson's Unity Walk. Friends and families were united in a common goal to raise awareness and funds to support research for better Parkinson's treatments and hopefully one day a cure. Through their collective efforts, more than $1.6 million in...

2014-07-22 12:30:17

Initiative to optimize patient care spearheaded by AbbVie and The Michael J. Fox Foundation to visit 11 cities in 2014 NEW YORK, July 22, 2014 /PRNewswire-USNewswire/ -- National Parkinson's organizations are working together to help provide Parkinson's patients and caregivers with knowledge and support to optimize their care through the "Partners in Parkinson's" strategic health initiative launched by The Michael J. Fox Foundation and AbbVie. Partners in Parkinson's offers...

2014-07-21 10:19:04

North Shore-Long Island Jewish (LIJ) Health System The brain network measures placebo effects in Parkinson's disease patients Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. Parkinson's disease is the second most common neurodegenerative disease in the...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related